EditorialPublished 2013

Global Current Trends in Drug Designing for Management of Type-2 Diabetes and Neurodegenerative Disorders

Authors: Haque A, Alam Q, Alam MZ, Kamal MA

Drug Designing: Open Access

Volume 2 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Neurodegenerative diseases (NDs) and Type 2 diabetes (T2D) are progressive disorder often advances with age. T2D is characterized by hyperglycaemia, insulin resistance or relative lack of insulin uptake whereas NDs are characterized by the decline in cognitive function, diffuse deposition of amyloid plaques and neurofibrillary tangles in AD and degeneration of dopaminergic neurons in substantia nigra, leading to a reduction of striatal dopamine (DA) levels in PD. Since conventional drugs fail to surpass the natural CNS protective barriers, therefore, in order to overcome these hurdles, targeted drug delivery is of foremost significance for the treatment of AD and PD. New generation of drugs has discovered through innovative nanotechnology approaches such as polymeric nanoparticles are promising candidates in the investigation of AD because nanoparticles are capable of opening the tight junctions, crossing the BBB. Thus, there is a need to adopt current trend and newer strategies such as nanotechnological, computational and gene therapy approaches for drug design and delivery.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Haque A”
  • BylineArticles whose byline prints “Alam Q”
  • BylineArticles whose byline prints “Alam MZ”
  • BylineArticles whose byline prints “Kamal MA”